Gri Bio Inc (GRI)

$1.47 +0.03 (2.08%)
Market Cap 3.08M
Revenue (ttm) 0.00
Net Income (ttm) -8.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 112,700
Avg Vol 256,788
Day's Range N/A - N/A
Shares Out 2.14M
Stochastic %K 90%
Beta -1.62
Analysts Strong Sell
Price Target $22.00

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 400 1170
Address:
2223 Avenida de la Playa, Suite 208, LA Jolla, United States
elkhro
elkhro Jul. 7 at 10:29 PM
$GRI will we see news tomorrow, a pump, and then r/s?
0 · Reply
Deadpresidentz
Deadpresidentz Jul. 7 at 8:12 PM
$GRI This is the closest sympathy to $MBIO except the float is lower and in phase 2. Has pulled huge moves in the past and had news last week.
1 · Reply
new_jack
new_jack Jul. 7 at 7:58 PM
$GRI break 1 fiddy???
0 · Reply
faithTrades
faithTrades Jul. 7 at 5:39 PM
$GRI what’s next for this stock?
0 · Reply
dButterz
dButterz Jul. 3 at 1:54 PM
$GRI
0 · Reply
dButterz
dButterz Jul. 3 at 12:01 AM
$GRI green it is 😜
0 · Reply
madan_shatri
madan_shatri Jul. 2 at 7:55 PM
$GRI is it bullish reversal ? Needs to watchout for next few days !
0 · Reply
Joe_088
Joe_088 Jul. 2 at 4:02 PM
$GRI or $CETX 2$
0 · Reply
Joe_088
Joe_088 Jul. 2 at 1:28 PM
$GRI load and wait⏰🌋
0 · Reply
dButterz
dButterz Jul. 2 at 12:43 PM
$GRI
0 · Reply
Latest News on GRI
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jul 1, 2025, 8:45 AM EDT - 6 days ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 11 days ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 21, 2025, 9:15 AM EDT - 6 weeks ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 16, 2025, 9:15 AM EDT - 7 weeks ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:35 AM EDT - 7 weeks ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 8, 2025, 8:45 AM EDT - 2 months ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 2 months ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 16, 2025, 8:35 AM EDT - 2 months ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 2, 2025, 4:05 PM EDT - 3 months ago

GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 3 months ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Apr 1, 2025, 11:07 AM EDT - 3 months ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 31, 2025, 8:00 AM EDT - 3 months ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 18, 2025, 9:05 AM EDT - 3 months ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 17, 2025, 8:05 AM EDT - 4 months ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Mar 11, 2025, 8:35 AM EDT - 4 months ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

GRI Bio Announces Reverse Stock Split

Feb 19, 2025, 4:05 PM EST - 4 months ago

GRI Bio Announces Reverse Stock Split

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 4 months ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 23, 2024, 9:00 AM EST - 7 months ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 21, 2024, 8:45 AM EST - 8 months ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 4:20 PM EST - 8 months ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 24, 2024, 8:30 AM EDT - 9 months ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Announces Exercise of Warrants

Oct 21, 2024, 5:35 PM EDT - 9 months ago

GRI Bio Announces Exercise of Warrants

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Oct 16, 2024, 8:45 AM EDT - 9 months ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 30, 2024, 8:30 AM EDT - 10 months ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 25, 2024, 8:45 AM EDT - 10 months ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:45 AM EDT - 10 months ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio to Present at the 2024 European Respiratory Congress

Sep 4, 2024, 8:45 AM EDT - 10 months ago

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:05 AM EDT - 11 months ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 22, 2024, 9:15 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 21, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 20, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 14, 2024, 9:05 AM EDT - 1 year ago

GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:00 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Apr 29, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Apr 25, 2024, 9:15 AM EDT - 1 year ago

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Apr 16, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Apr 8, 2024, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Apr 1, 2024, 7:35 AM EDT - 1 year ago

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Mar 28, 2024, 9:00 AM EDT - 1 year ago

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

Mar 14, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Mar 4, 2024, 8:30 AM EST - 1 year ago

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

Feb 23, 2024, 7:50 AM EST - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

SINT

GRI Bio Announces Pricing of $5.5 Million Public Offering

Feb 2, 2024, 8:00 AM EST - 1 year ago

GRI Bio Announces Pricing of $5.5 Million Public Offering

elkhro
elkhro Jul. 7 at 10:29 PM
$GRI will we see news tomorrow, a pump, and then r/s?
0 · Reply
Deadpresidentz
Deadpresidentz Jul. 7 at 8:12 PM
$GRI This is the closest sympathy to $MBIO except the float is lower and in phase 2. Has pulled huge moves in the past and had news last week.
1 · Reply
new_jack
new_jack Jul. 7 at 7:58 PM
$GRI break 1 fiddy???
0 · Reply
faithTrades
faithTrades Jul. 7 at 5:39 PM
$GRI what’s next for this stock?
0 · Reply
dButterz
dButterz Jul. 3 at 1:54 PM
$GRI
0 · Reply
dButterz
dButterz Jul. 3 at 12:01 AM
$GRI green it is 😜
0 · Reply
madan_shatri
madan_shatri Jul. 2 at 7:55 PM
$GRI is it bullish reversal ? Needs to watchout for next few days !
0 · Reply
Joe_088
Joe_088 Jul. 2 at 4:02 PM
$GRI or $CETX 2$
0 · Reply
Joe_088
Joe_088 Jul. 2 at 1:28 PM
$GRI load and wait⏰🌋
0 · Reply
dButterz
dButterz Jul. 2 at 12:43 PM
$GRI
0 · Reply
FloatRaider
FloatRaider Jul. 1 at 7:27 PM
$GRI starting to heat up 💥 ATER dip = opportunity Nothing goes straight up. Price cooling after breakout = textbook retest 🔄Still riding major catalysts: Temu ✅ Mercado Libre ✅ Buyback ✅Analyst target still $4–8 🚀
0 · Reply
Joe_088
Joe_088 Jul. 1 at 7:19 PM
$GRI
0 · Reply
mendez628
mendez628 Jul. 1 at 12:59 PM
$GRI good news today, get ready for the dump
1 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jul. 1 at 12:55 PM
$GRI GRI Bio Completes Enrollment In Phase 2a Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis; 2- And 6- Week Interim Safety Results Demonstrated GRI-0621 To Be Safe And Well-Tolerated In The First 12 And 24 Patients Evaluated, Respectively
0 · Reply
Joe_088
Joe_088 Jul. 1 at 12:55 PM
$GRI come on good news
0 · Reply
ahTony
ahTony Jul. 1 at 12:53 PM
$GRI news out.
0 · Reply
elkhro
elkhro Jul. 1 at 12:51 PM
$GRI
1 · Reply
elkhro
elkhro Jun. 30 at 10:07 PM
$GRI I mean good news so far
0 · Reply
Joe_088
Joe_088 Jun. 30 at 5:48 PM
$GRI 5k more
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 30 at 3:15 PM
$GRI Load up...
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 30 at 3:15 PM
$GRI PT 2 https://finance.yahoo.com/news/gri-bio-reports-six-week-145457078.html
0 · Reply
Gellener
Gellener Jun. 30 at 8:06 AM
$GRI ... 1.10 support and then ...
0 · Reply